A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes

OBJECTIVES: We assessed the safety of ustekinumab (a monoclonal antibody used in psoriasis to target the IL-12 and IL-23 pathways) in a small cohort of recent-onset (<100 days of diagnosis) adults with type 1 diabetes (T1D) by conducting a pilot open-label dose-finding and mechanistic study (NCT0...

Descripción completa

Detalles Bibliográficos
Autores principales: Marwaha, Ashish K, Chow, Samuel, Pesenacker, Anne M, Cook, Laura, Sun, Annika, Long, S Alice, Yang, Jennie H M, Ward-Hartstonge, Kirsten A, Williams, Evangelia, Domingo-Vila, Clara, Halani, Khalif, Harris, Kristina M, Tree, Timothy I M, Levings, Megan K, Elliott, Thomas, Tan, Rusung, Dutz, Jan P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769169/
https://www.ncbi.nlm.nih.gov/pubmed/35072168
http://dx.doi.org/10.1093/immadv/ltab022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769169/
https://www.ncbi.nlm.nih.gov/pubmed/35072168
http://dx.doi.org/10.1093/immadv/ltab022

Ejemplares similares